Skip to main content

MoneyWorks4Me

Lupin informs about press release

27 Mar 2023 Evaluate

Lupin has informed that it enclosed a Press Release regarding receipt of tentative approval from the US FDA for the Company’s Abbreviated New Drug Application, Valbenazine Capsules, 40 mg, 60 mg, and 80 mg, to market a generic equivalent of Ingrezza Capsules, 40 mg, 60 mg, and 80 mg, of Neurocrine Biosciences, Inc.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1795.70
Dr. Reddys Labs. 1350.10
Cipla 1371.40
Lupin 1987.10
Zydus Lifesciences 1203.00
View more..